Influenza Vaccines for the World

19-21 April 2017, CHUVUniversity of Lausanne, Lausanne, Switzerland

  • Increase font size
  • Default font size
  • Decrease font size

Posters

Final Conference Programme | Poster Session

Poster 101
‘Core-shell implants suitable to obtain a delayed IgG1 antibody response in mice’
Philip A. Born1, Katie Amssoms2, Ben De Clerck2, Ellen Van Gulck3, Henderik W. Frijlink1, Niels Grasmeijer1, Guenter Kraus3, Roger Sutmuller3, Kenny Simmen4, Lieven Baert5 and Wouter L.J. Hinrichs1 (1 Department of Pharmaceutical Technology and Biopharmacy, University of Groningen; 2 Discovery Sciences, Janssen Research & Development, a division of Janssen Pharmaceutica NV; 3 Infectious Diseases & Vaccines Therapeutic Area, Janssen Research & Development, a division of Janssen Pharmaceutica NV; 4 Johnson & Johnson Innovation Center; 5 Jalima Pharma bvba)

Poster 102
‘Induction of hetero-subtypic immunogenicity by influenza DNA vaccine based on hemagglutinin using a conventional adjuvant alum phosphate’
Hwajung Yi, Ki-Woen Seo, Eun Young Jang, Mi-Seon Lee, Junhyung Cho, Joo-Yeon Lee and Kisoon Kim (Division of Influenza Virus, Korea National Institute of Health, Korea Centers for Diseases Control and Prevention, OHTAC, 187, Cheongju-si, Chungbuk-do, 28159, Republic of Korea)

Poster 103
‘Roles of non-neutralizing antibodies against hemagglutinin of the highly pathogenic avian H5N1 influenza virus in human’
Mi-Seon Lee, Eun Young Jang, Junhyung Cho, Joo-Yeon Lee, Kisoon Kim and Hwajung Yi (Division of Influenza Virus, Korea National Institute of Health, Korea Centers for Diseases Control and Prevention, OHTAC, 187, Cheongju-si, Chungbuk-do, 28159, Republic of Korea)

Poster 104
‘Plant-made virus-like particles bearing influenza hemagglutinin mimic the interactions of influenza virus with human antigen-presenting cells in vitro
Alexander I. Makarkov1, Sabrina Chierzi1, Stéphane Pillet1,2, Nathalie Charland2, Nathalie Landry2 and Brian J. Ward1 (1 Research Institute of McGill University Health Centre and Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Quebec, Canada; 2 Medicago Inc, Ste-Foy, Quebec, Canada)

Poster 105
‘Commitment to vaccination against flu at pregnant women and health workers’
N.I. Briko and T.S. Saltykova (Sechenov First Moscow State Medical University, Moscow, Russia)

Poster 106
‘Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro
Hilary E. Hendin1,2, Stephane Pillet2,3, Amanda N. Lara2,4, Nathalie Charland3, Nathalie Landry3 and Brian J. Ward2 (1 Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada; 2 Research Institute of McGill University Health Centre, Glen Site, Montreal, Quebec, Canada; 3 Medicago Inc., Quebec, Quebec, Canada; 4 University of Sao Paulo School of Medicine, Cerqueira César, São Paulo, Brazil)

Poster 107
‘Layer-by-layer coating of whole inactivated influenza virus (WIV): A single-shot vaccine approach?’
C. Lemoine1,2, M. Marti Favre1, V. Jakob1, W. Jiskoot3, N. Collin1, G. Borchard2 and C. Barnier-Quer1 (1 Vaccine Formulation Laboratory, University of Lausanne, Lausanne, Switzerland; 2 School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Lausanne, Switzerland; 3 Division of Drug Delivery Technology, Leiden Academic Centre for Drug Research, Leiden, The Netherlands)

Poster 108
‘Clinico-radiological profile, polymerase chain reaction (pcr) – positivity and outcome – analysis in hospitilized suspected h1n1 pneumonia: Efficiency assessment of health care delivery system. A pilot study’
Muhammad Yousaf Khan, Zafar Iqbal, Jawad Khan and Muhammad Amin (Affiliation to be confirmed)

Poster 109
‘The experience of school-based Influenza vaccination in Taiwan’
Shu-Er Yang (CDC, Taiwan)

Poster 110
‘Single shot vaccines with novel CMS adjuvant’
Peter Paul Platenburg1, Luuk Hilgers1, Jeffrey Bajramovic2, Jennifer Veth2, Anneloes Dirks3, Tineke Coenen3, Robert Sauerwein4, Will Roeffen4, Marie Pohl5, Geert van Amerongen5, Koert J. Stittelaar5 and Han van den Bosch1 (1 LiteVax BV, Oss, The Netherlands; 2 Biomedical Primate Research Centre, Rijswijk, The Netherlands; 3 BioXpert BV, Schaijk, The Netherlands; 4 Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 5 Viroclinics Biosciences BV, Rotterdam, The Netherlands)

Poster 111
‘Development and validation of a non-egg-adapted wild-type Influenza A H3N2 strain (A/Belgium/4217/2015 (H3N2)) as challenge agent for human volunteer challenge studies’
M. Schutten1, B. Speder2, R. Jeeninga3, V. van Cleave4, A. Lovatt5, J. Sheridan2 and A. Wildfire2 (1 Clinical Virology and Diagnostics, Alkmaar, The Netherlands; 2 SGS LifeSciences, Mechelen, Belgium; 3 Viroclinics, Rotterdam, The Netherlands; 4 Meridian LifeSciences, Memphis, United States of America; 5 SGS Vitrology, Glasgow, United Kingdom)

Poster 112
‘Adjuvanted mini-HA UFV4900 induces broadly influenza neutralizing antibodies in pre-exposed non-human primates which protect mice from lethal influenza challenge’
Joan E.M. van der Lubbe, Jeroen Huizingh, Johan Verspuij, Lisanne Tettero, Sonja Schmit-Tillemans, Liesbeth Dekking, Boerries Brandenburg, Ted Kwaks, Jeroen Tolboom, Tobias Kamphuis, Wim Meijberg, Hanneke Schuitemaker, Roland Zahn, Ramon Roozendaal and Harmjan Kuipers (Janssen Vaccines and Prevention BV, Pharmaceutical Companies of Johnson & Johnson, Leiden, The Netherlands)

Poster 113
‘An mRNA-based technology for the next generation of prophylactic influenza vaccines’
E. Jasny, J. Lutz, S. Rauch, S. Lazzaro, P. Baumhof, H. Heidenreich, B. Petsch and M. Fotin-Mleczek (CureVac AG, Tübingen, Germany)

Poster 114
To be confirmed

 

IVW 2017 Delegates

Login details will be supplied after you have registered for the event.


IVW 2017 Sponsors

  • ISIRV
  • MedicaGo
  • Janssen
  • InDevR
  • Vaxart
  • Fraunhofer
  • Eurocine Vaccines
  • VisMederi
  • Protein Sciences
  • hVIVO
  • MedImmune
  • Biondvax
  • FluConsult
  • Nanopass
  • APACI
  • Inovio
  • Sanofi Pasteur

IVW 2017 Downloads

IVW 2017 Leaflet

IVW 2017 Mailing List

Name
E-mail Address
What is 3+2-1?